Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr;85(2):82-7.
doi: 10.1136/sti.2008.032300. Epub 2008 Nov 5.

Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception

E S Machado  1 , C B Hofer, T T Costa, S A Nogueira, R H Oliveira, T F Abreu, L A Evangelista, I F A Farias, R T C Mercadante, M F L Garcia, R C Neves, V M Costa, J S Lambert
Affiliations

Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception

E S Machado et al. Sex Transm Infect. 2009 Apr.

Abstract

Objective: The potential adverse effects of antiretroviral drugs during pregnancy are discrepant and few studies, mostly from Europe, have provided information about pregnancy outcomes of those already on treatment at conception. The aim of this study was to investigate the impact of antiretrovirals (ARVs) on pregnancy outcome according to the timing of treatment initiation in a cohort of pregnant women from Brazil infected with HIV.

Methods: A prospective cohort of 696 pregnant women followed up in one single centre between 1996 and 2006 was studied. Patients who had ARV treatment before pregnancy were compared with those treated after the first trimester. The outcomes evaluated were preterm delivery (PTD) (<37 weeks), severe PTD (<34 weeks), low birth weight (LBW) (<2500 g) and very LBW (<1500 g).

Results: Patients who were using ARVs pre-conception had higher rates of LBW (33.3% vs 16.5%; p<0.001) and a similar trend for PTD (26.3% vs 17.7%; p = 0.09). Stratification by type of therapy (dual vs highly active antiretroviral therapy (HAART)) according to timing of initiation of ARVs showed that patients who use HAART pre-conception have a higher rate of PTD (20.2% vs 10.2%; p = 0.03) and LBW (24.2% vs 10.2%; p = 0.002). After adjusting for several factors, HAART used pre-conception was associated with an increased risk for PTD (AOR 5.0; 95% CI 1.5 to 17.0; p = 0.009) and LBW (OR 3.6; 95% CI 1.7 to 7.7; p = 0.001).

Conclusions: We identified an increased risk for LBW and PTD in patients who had HAART prior to pregnancy.

PubMed Disclaimer

References

    1. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173–1180. - PubMed
    1. Nogueira SA, Abreu T, Oliveria R, Araujo L, Costa R, Andrade M, et al. Successful prevention of HIV transmission from mother to infant in Brazil using a multidisciplinary team approach. Braz J Infect Dis. 2001;5:78–86. - PubMed
    1. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484–494. - PubMed
    1. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:458–465. - PubMed
    1. Centers for Disease Control and Prevention (CDC) Achievements in public health. Reduction in perinatal transmission of HIV infection – United States, 1985–2005. MMWR Morb Mortal Wkly Rep. 2006;55:592–597. - PubMed

Publication types

MeSH terms

Substances